Lornoxicam

Chemical formula: C₁₃H₁₀ClN₃O₄S₂  Molecular mass: 371.81 g/mol  PubChem compound: 54690031

Therapeutic indications

Lornoxicam is indicated for:

Pain

Population group: only adults (18 years old or older)

Pain

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Osteoarthritis

Population group: only adults (18 years old or older)

Osteoarthritis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Rheumatoid arthritis

Population group: only adults (18 years old or older)

Rheumatoid arthritis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Lornoxicam is contraindicated in the following cases:

Pregnancy

Pregnancy

Thrombocytopenia

Thrombocytopenic disorder

Severe heart failure

Heart failure New York Heart Assosiation Class IV

Gastro-intestinal bleeding

Gastrointestinal hemorrhage

Bleeding

Bleeding

Peptic ulcer

Peptic ulcer

Severe hepatic impairment

Hepatic failure stage IV

Severe renal impairment

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2013: XEFO Powder and solvent for solution for injection
Summary of Product Characteristics (SPC) 2015: XEFO Film-coated tablets
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈